Orgenesis Inc., a global biotech company working to transform the delivery of cell and gene therapies (CGTs), has entered into an agreement to acquire the assets of Tamir Biotechnology, Inc., including ranpirnase, TamirBio’s broad spectrum anti-viral platform. The acquisition will be completed for total consideration of approximately $16.8 million. Orgenesis plans to combine ranpirnase with its co-developed Bioxome technology for enhanced payload delivery directly to cells. TamirBio is a clin...